Recap - Auxilium Pharmaceuticals (AUXL) was approached by Endo Pharmaceuticals (ENDP) this week in a $2.2 billion unsolicited acquisition attempt. The stock and cash deal would represent … Continue Reading
Read NowInsights - Avanir Pharmaceuticals (AVNR) added $400 million to its valuation on Monday morning with positive results from a phase 2 trial evaluating the safety and efficacy of AVP-923 in Alzheimer’s … Continue Reading
Read NowRecap - A dual event in the obesity space this week, the U.S. FDA approved Orexigen Therapeutics’ (OREX) weight loss pill Contrave just one day before an … Continue Reading
Read NowInsights - Hyperion Therapeutics (HPTX) shuttered development of DiaPep277 in newly diagnosed Type 1 diabetes on Monday, citing improper trial conduct from the drug’s original developer, Andromeda Biotech. Hyperion acquired … Continue Reading
Read NowResearch - Why we're booking gains on Keryx (KERX) and an options strategy for the Sept. 7 PDUFA decision on Zerenex.
Read NowInsights - Infinity Pharmaceuticals (INFI) and AbbVie Inc. (ABBV) have entered into a major partnership to develop and commercialize duvelisib (IPI-145), Infinity’s oral phosphoinositide-3-kinase (PI3K) inhibitor. PI3K inhibitors were the cat’s meow in … Continue Reading
Read Now
